Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study

Overview of attention for article published in Journal of Cancer Research and Clinical Oncology, April 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#30 of 2,632)
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 3 news outlets

twitter: 6 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 30 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Long-Term Benefits Seen With Trabectedin With PLD for Recurrent Ovarian Cancer

Oncology Nurse Advisor , 19 Jun 2018

Trabectedin with pegylated liposomal doxorubicin (PLD) may provide long-term benefits for pre-treated patients with platinum-sens…

Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting

UBM Medica, 17 May 2018

The combination of trabectedin and pegylated liposomal doxorubicin (PLD) offered clinical benefit and was reasonably well…

Ovarian Cancer Patients May Benefit From Trabectedin With PLD

Clinical Advisor, 16 May 2018

Trabectedin with pegylated liposomal doxorubicin (PLD) may provide long-term benefits for pre-treated patients with platinum-sens…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.